Corvas shifts rNAPc2 priorities

CVAS said it will focus on the development of its rNAPc2 to treat acute coronary syndromes, including unstable angina, rather than for deep vein thrombosis (DVT). The company said that following discussions with the FDA, CVAS would have to conduct another Phase II trial to establish a fixed dosing regimen in the DVT indication. CVAS said that unstable angina represents a greater market opportunity, and that development of rNAPc2 for DVT will depend on finding a partner. The product is an injectable recombinant nematode anticoagulant protein. ...